VolitionRx Reports 23% Revenue Growth to $1.28 Million, Faces Ongoing Operating Losses

VolitionRx Limited reported its financial results for the nine months ending September 30, 2025, revealing total revenues of $1.28 million, a 23% increase from $1.04 million in the same period of 2024. The revenue growth was primarily driven by a significant rise in service revenues, which more than doubled to $366,150, while product revenues saw a modest increase to $914,200. Despite the revenue growth, the company continued to experience substantial operating losses, reporting a net loss of $17.2 million, down from $21.4 million in the prior year, reflecting a 20% improvement.

The company's operating expenses decreased to $18.2 million from $22.3 million year-over-year, largely due to a 36% reduction in research and development costs, which fell to $7.6 million as clinical trials concluded. General and administrative expenses rose by 21% to $7.7 million, attributed to increased legal and professional fees, as well as higher stock-based compensation. Sales and marketing expenses also decreased significantly, down 29% to $2.9 million, reflecting a reduction in personnel and marketing costs.

In terms of operational metrics, VolitionRx's cash and cash equivalents dwindled to $199,407 by the end of the reporting period, down from $3.26 million at the start of the year. The company has been actively pursuing financing options to support its operations, including a series of capital raises throughout 2025. Notably, the company raised approximately $11 million through various financing activities, including a senior secured convertible note and multiple registered direct offerings.

Strategically, VolitionRx has made significant strides in expanding its product offerings and market presence. The company launched its Nu.Q® Vet Cancer Test in multiple countries, including the UK, Ireland, and Japan, and signed a research license agreement with Werfen for its Nu.Q® H3.1 NETs assay. Additionally, a co-marketing agreement with Hologic aims to enhance customer access to the Nu.Q® Discover service. These initiatives are part of VolitionRx's broader strategy to transition from research and development to commercialization, focusing on the early detection and monitoring of diseases through innovative blood tests.

Looking ahead, VolitionRx faces challenges related to its liquidity and ongoing operational losses, which have raised concerns about its ability to continue as a going concern. The company is actively seeking additional capital through licensing agreements, equity sales, and grant funding to sustain its operations and advance its product development efforts. Management remains focused on implementing cost-saving measures and enhancing its operational efficiency to navigate the financial landscape effectively.